Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Research: Forums: Live Discussions
Live Discussions

Updated 5 July 2006

M1 Receptors Play a Central Role in AD Pathology and Cognition


Frank LaFerla
Our thanks to Neuron for providing free access to this paper for the purposes of this live discussion.

Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, LaFerla FM. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron. 2006 Mar 2;49(5):671-82. Read paper

View Presentation
You will need Windows Media Player (PC Mac) to view this presentation.

Frank LaFerla led this Webinar on 5 July 2006. Readers are invited to submit additional comments by using our Comments form at the bottom of the page.


Background Text

ARF News Story: Cholinergic Transmission and Aβ: Boosting M1 Receptors Treats Model

An impressive data set that appeared yesterday in Neuron shows that a specific M1 muscarinic receptor agonist can reverse both cognitive deficits as well as the amyloid and tau pathology in the APP/PS1/tau triple transgenic mice mouse model of AD. The publication, from Frank LaFerla and colleagues from the University of California at Irvine and Abraham Fisher at the Israel Institute for Biological Research in Ness Ziona, advances a story that garnered significant attention when the investigators presented their preliminary results on the small molecule AF267B at the 2004 Society for Neurosciences meeting in San Diego.

The compound was licensed at that time to TorreyPines Therapeutics, Inc. (formerly Neurogenetics, Inc.) in San Diego, who made their own news this week by announcing that they have initiated a second Phase I trial of the compound in humans. The trial, which is expected to yield results as soon as next June, might give an early indication of whether the compound is capable of affecting Aβ or tau metabolism or cognitive function in humans...Read more



  Submit a Comment on this Live Discussion
Cast your vote and/or make a comment on this live discussion. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
 


Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
Live Discussion FAQs

Webinar: A Webinar is a seminar conducted remotely over the Web. Attendees view the slides through their Web browser and hear the presentations over their own telephones.

Registration: All participants are to register by clicking on the "Register for the Webinar" link.

Access: After you register, you will receive an e-mail with a link to the Webinar and a phone number.

View Webinar Instructions

Early Detection Survey Results
The Alzheimer Disease Early Detection Surveys were designed to gauge perceptions and knowledge of early detection of Alzheimer disease as a follow-up to our Early Detection Webinar. The surveys were developed in collaboration with the Geoffrey Beene Foundation.
View Researcher Survey Results [.pdf].
View Public Survey Results [.pdf].
AlzPossible Initiative
The AlzPossible Initiative is an innovative "center without walls" that enables skilled individuals to share their knowledge about best practices in Alzheimer caregiving through this open forum.
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad